These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32105179)

  • 1. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept.
    Bonafede M; Oko-Osi H; Gharaibeh M; Manjelievskaia J; Lopez-Gonzalez L; Collier DH; Stolshek BS
    J Manag Care Spec Pharm; 2020 Feb; 26(2):211-220. PubMed ID: 31823689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
    Incerti D; Hernandez EJM; Tkacz J; Jansen JP; Collier D; Gharaibeh M; Moore-Schiltz L; Stolshek BS
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1236-1242. PubMed ID: 32996384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
    Gharaibeh M; Bonafede M; McMorrow D; Hernandez EJM; Stolshek BS
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
    Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
    Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis.
    Delate T; Meyer R; Jenkins D
    J Manag Care Spec Pharm; 2017 Aug; 23(8):798-808. PubMed ID: 28737988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
    Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
    J Rheumatol; 2013 Oct; 40(10):1658-68. PubMed ID: 23908446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 17. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
    Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
    J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
    Bonafede M; Johnson BH; Tang DH; Shah N; Harrison DJ; Collier DH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1656-63. PubMed ID: 26097194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
    Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
    Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.